Please upgrade your browser.
Duplicated 1q might be a secondary mutations associated with disease progression. Trisomy of 1q has also been linked to metastatic potential of colon and renal cell carcinomas.
RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma
Vascular endothelial growth factors (VEGFs) are crucial regulators of angiogenesis and vasculogenesis.
Founded in 1990, the Kidney Cancer Association (KCA) is a charitable organization made up of patients, family members, physicians, researchers, and other health professionals globally. We fund, promote, and collaborate with the National Cancer Institute, American Society for Clinical Oncology, American Urological Association, and other institutions on research projects
This is the first report of this kind of presentation.
Surgery is the primary treatment of skeletal metastases from renal cell carcinoma, because radiation and chemotherapy frequently are not effecting the survival.
Total Pancreatectomy for Metastatic Renal Cell Carcinoma with Marked Extension into the Main Pancreatic Duct
The authors discuss an extremely rare case of pancreatic metastasis from RCC, with marked extension into the main pancreatic duct.
The authors describe a rare case of a metastatic tumour in the colon arising from renal cell carcinoma.
Pure Sarcomatous Recurrence of Clear Cell Renal Carcinoma Following Radical Nephrectomy and Dendritic Cell Vaccination
The authors discuss the patient's history and pathology images, treatments, and the potential effects of dentritic cell-tumor cell hybrid vaccination on the natural history of renal cell carcinoma.
TLN-4601, a small molecule derived from a nonpathogenic microorganism and TLN-232, a peptide used for the treatment of multiple oncology indications such as metastatic melanoma, renal cell carcinoma, and pancreatic cancer.
The National Institute for health and Clinical Excellence has turned down the drug called everolimus, also known as Afinitor, saying it does not offer enough benefit to patients to justify the cost.
|NeonCRM by Neon One|